ARHGAP39 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat human T lymphocyte line, designed for loss-of-function analysis of the ARHGAP39 gene. This product consists of a heterogeneous pool of cells carrying diverse target-gene disruptions introduced by non-homologous end joining, providing a robust model to study ARHGAP39-dependent signaling without the need for clonal isolation. The polyclonal format preserves genetic diversity within the population, enabling functional evaluation of ARHGAP39 ablation across a range of editing outcomes and minimizing clonal artifacts.
The Jurkat host cell line is a well-established model originating from acute T cell leukemia, representing a lymphoblastoid T cell phenotype. These cells are extensively utilized to dissect T cell activation, apoptosis, and cytokine production, offering a tractable system for exploring T cell receptor (TCR)-proximal signaling events. Jurkat cells express key components of the TCR/CD3 complex and downstream mediators, making them particularly suited for studies linking cytoskeletal regulation to immune function. Their suspension growth and rapid proliferation facilitate high-throughput applications and reproducible assay formats.
ARHGAP39 functions as a GTPase-activating protein (GAP) that negatively regulates Rho family GTPases, including RhoA, Rac1, and Cdc42, by accelerating their intrinsic GTP hydrolysis. This action downregulates active GTP-bound forms, thereby attenuating actin polymerization and actomyosin contractility. ARHGAP39 is activated by upstream signals from the TCR/CD3 complex, integrin receptors, and growth factor receptors, and it interacts directly with RhoA, Rac1, Cdc42, and actin filaments. Downstream, ARHGAP39 suppresses RhoA-ROCK, Rac1-PAK, and Cdc42-WASP/Arp2/3 pathways, ultimately modulating LIMK, cofilin, and Arp2/3-mediated actin remodeling. The integrated signaling network includes core components such as ROCK1, PAK1, and the Arp2/3 complex, placing ARHGAP39 at a critical node controlling cytoskeletal dynamics.
In the Jurkat cell context, ARHGAP39 disruption leads to sustained Rho GTPase signaling, resulting in enhanced actin remodeling, altered cell adhesion, and potential hyperactivation of TCR-mediated responses. This model enables researchers to dissect how ARHGAP39 orchestrates the balance between actin polymerization and depolymerization in T cells, impacting migration, immunological synapse formation, and effector functions. Given the role of Rho GTPases in leukemia dissemination, ARHGAP39 knockout Jurkat cells serve as a relevant platform for examining mechanisms of T-cell leukemia motility and invasiveness, as well as broader implications for immune dysregulation.
Typical applications encompass flow cytometric measurement of F-actin content, transwell migration assays, RhoA GTPase pull-down activation assays, and western blot detection of phospho-cofilin as a readout of ROCK/LIMK pathway activity. Immunofluorescence staining of actin stress fibers and TCR-stimulated CD69 expression or cytokine secretion assays are also routinely employed. These cells support investigations into Rho GTPase regulation during T cell migration and activation, screening for cytoskeletal modulators, and validation of ARHGAP39 downstream effectors. For further information or custom usage inquiries, please contact Ascent Research.
